id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0917-0006,FDA,FDA-2025-E-0917,Determination of Regulatory Review Period for Purposes of Patent Extension; ALHEMO,Notice,Determinations,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,2026-02-28T04:59:59Z,2025-12-29T20:38:53Z,2025-23863,0,0,09000064b9106d07
FDA-2025-E-0917-0005,FDA,FDA-2025-E-0917,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-08-19T04:00:00Z,2025,8,2025-08-19T04:00:00Z,,2025-08-19T20:26:21Z,,0,0,09000064b8f07d0a
FDA-2025-E-0917-0004,FDA,FDA-2025-E-0917,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-07-25T04:00:00Z,2025,7,2025-07-25T04:00:00Z,,2025-07-25T20:49:24Z,,0,0,09000064b8e9d687
FDA-2025-E-0917-0003,FDA,FDA-2025-E-0917,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-06-30T04:00:00Z,2025,6,2025-06-30T04:00:00Z,,2025-06-30T19:53:00Z,,0,0,09000064b8e4297c
FDA-2025-E-0917-0001,FDA,FDA-2025-E-0917,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-03-26T04:00:00Z,2025,3,2025-03-26T04:00:00Z,,2025-03-26T11:37:16Z,,0,0,0900006486a30eb0
FDA-2025-E-0917-0002,FDA,FDA-2025-E-0917,Patent Extension Application from Novo Nordisk Inc.,Other,Application,2025-03-26T04:00:00Z,2025,3,2025-03-26T04:00:00Z,,2025-03-26T11:37:22Z,,0,0,0900006486a396f5